
News|Articles|February 1, 2003
- Applied Clinical Trials-02-01-2003
New Ways to Recruit Trial Subjects
Author(s)Faiz Kermani, Ph.D, Pietro Bonacossa
To minimize time to market, sponsors must explore new subject recruitment techniques.
Advertisement
Clinical trials are a vital step toward bringing new drugs to market. U.S.-based clinical trial activities increased by 6% in 2001, the largest rise since 1990.1 But although pharmaceutical companies pay close attention to the science when designing their clinical trials, few consider how they will get enough subjects to participate. As a result, most trials are plagued by delays that can cost pharmaceutical companies millions of missed sales. Delays in getting a drug to market are estimated to cost companies around $1 million a day.2
Articles in this issue
almost 24 years ago
Clinical Trials in Indiaalmost 24 years ago
Using Mock Inspections to Prepare for FDA GCP Inspectionsalmost 24 years ago
Tweaking the EU Rules on Clinical Trialsalmost 24 years ago
AIDS Campaign Spotlights Global Clinical Researchalmost 24 years ago
The Woodsman?s Talealmost 24 years ago
A 6-Month Process for Planning Multinational Clinical TrialsAdvertisement
Related to this article

Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.

ACT Brief: AI Trial Matching Access, IRB Oncology Expertise, and Livsayis Myasthenia Gravis Approval
In today’s ACT Brief, we examine why AI-enabled trial matching could close the oncology access gap, why IRBs need substantive therapeutic expertise, and how FDA approved Regeneron’s Livsayis, a treatment given four times a year for myasthenia gravis.

Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.

In this Q&A, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, discusses why so many patients from underrepresented groups are never asked to join a clinical trial, how AI-enabled matching and screening can make oncology access more consistent, and why the conversation with the patient must stay human.

In today’s ACT Brief, we examine how trial matching built into standard care can replace reliance on physician memory, how federal funding cuts and FDA staff losses are pressuring biotech, and why FDA is without a commissioner nominee after the White House withdrew Heidi Overton.

Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, outlines how integrating trial matching with standard of care workflows and uniform screening can replace reliance on physician memory with timely, consistent nudges.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Next Evolution of Patient-Centered Trials Starts with Design
2
ACT Brief: AI Trial Matching Access, IRB Oncology Expertise, and Livsayis Myasthenia Gravis Approval
3
ACT Brief: Trial Matching Nudges, Federal Pressures on Biotech, and FDA Leadership Vacancy
4
What Care Teams Should Do Differently So Every Eligible Patient Hears About a Trial
5
